Characterization of Lentiviral Gene-modified CAR T Cell Therapies
Originally presented at the Cell Therapy Analytical Development Summit 2023, this poster shares data demonstrating our comprehensive analytics, which is essential to any cell therapy candidate. It showcases our recent advances in lentiviral infectious titer and VCN via ddPCR, CAR T immunophenotyping release testing, and customized potency assay development, overviewing a robust and customizable platform to drive forward improved CAR T cell therapies.
Since comprehensive CAR T cell therapy production analytics are required for effective production and release testing, precise, repeatable, and customizable measurements are of utmost importance.
Submit your information to download the poster and learn how our in-house developed assays, each customizable to CARs of interest, can dramatically improve the characterization of CAR T cell functionality and bring your cell therapy one step closer to reality.
About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
